Author:
Briggs Jonathan H.,Miller Thomas P.
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Shipp MA, Harrington DP: A predictive model for aggressive non-Hodgkin’s lymphoma: the International NHL Prognostic Factor Project. N Engl J Med 1993, 329:987–994.
2. Romaguera JE, Velasquez WS, Silvermintz KB, et al.: Surgical debulking is associated with improved survival in Stage I-II diffuse large cell lymphoma. Cancer 1990, 66:267–272.
3. Aref A, Narayan S, Tekyi-Mensah S, et al.: Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin’s lymphoma. Radiat Oncol Investig 1999, 7:186–191.
4. Glick JH, Kim K, Earle J, O’Connell MJ: An ECOG randomized phase III trial of CHOP vs. CHOP plus radiotherapy for intermediate grade early stage non-Hodgkin’s lyphoma[abstract]. Proc ASCO 1995, 14:391a. This phase III ECOG trial demonstrates the benefit of the addition of involved-field radiotherapy in patients with bulky and extranodal stage I and stage II intermediate-grade lymphomas receiving CHOP chemotherapy. Patients receiving the combined modality approach had significantly improved disease-free survival and failure-free survival, whereas overall survival rates approached a significant improvement.
5. Fuller LM, Krasin MJ, Velasquez WS, et al.: Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-bleomycin and radiation. Int J Radiat Oncol Biol Phys 1995, 31:3–11.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献